此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Onyx™ 液体栓塞 IDE 临床研究

2026年10月8日 更新者:Medtronic Endovascular

PELE IDE 临床研究,外周 Onyx™ 液体栓塞安全性以及 Onyx™ LES 栓塞外周脉管系统动脉出血的有效性

The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.

研究概览

详细说明

This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.

Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.

This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.

研究类型

介入性

注册 (估计的)

119

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Arizona
      • Phoenix、Arizona、美国、85054
        • 招聘中
        • Mayo Clinic
        • 接触:
        • 首席研究员:
          • Sadeer Alzubaidi, MD
        • 接触:
          • Yahaira Parker
    • California
      • Irvine、California、美国、92627
      • Los Angeles、California、美国、90095
        • 招聘中
        • University of California Los Angeles
        • 接触:
        • 首席研究员:
          • Jessica Stewart, MD
      • Palo Alto、California、美国、94304
        • 招聘中
        • Stanford Medical Center
        • 接触:
          • Andrew Picel, MD
        • 接触:
    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • UCHealth University of Colorado Hospital
        • 接触:
        • 首席研究员:
          • Eduardo Bent Robinson, MD
    • Connecticut
    • Illinois
      • Chicago、Illinois、美国、60637
    • Iowa
      • Iowa City、Iowa、美国、52242
        • 招聘中
        • University of Iowa Hospitals and Clinics
        • 首席研究员:
          • Michael Hummel, MD
        • 接触:
    • Massachusetts
    • Nebraska
      • Omaha、Nebraska、美国、68124
        • 招聘中
        • CHI Health Creighton University Medical Center-Bergan-Mercy
        • 接触:
        • 首席研究员:
          • Patrick Harty
    • New Jersey
      • Newark、New Jersey、美国、07103
        • 招聘中
        • Rutgers New Jersey Medical School
        • 首席研究员:
          • Abhishek Kumar, MD
        • 接触:
    • New York
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • 招聘中
        • University of North Carolina at Chapel Hill
        • 首席研究员:
          • Nima Kokabi, MD
        • 接触:
    • Ohio
      • Cleveland、Ohio、美国、44106
        • 招聘中
        • University Hospitals Cleveland Medical Center
        • 接触:
        • 首席研究员:
          • Salim Abboud, MD
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University
        • 接触:
          • Mina Makary, MD
        • 接触:
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15237
        • 招聘中
        • University of Pittsburgh Medical Center
        • 首席研究员:
          • Paula Novelli, MD
        • 接触:
    • Tennessee
      • Nashville、Tennessee、美国、37212
        • 招聘中
        • Vanderbilt University Medical Center
        • 接触:
        • 首席研究员:
          • Anthony Borgmann, MD
    • Texas
      • Dallas、Texas、美国、75235
        • 招聘中
        • Univ Of Texas Southwestern
        • 首席研究员:
          • Sanjeeva Kalva, MD
        • 接触:
      • Houston、Texas、美国、77030

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

22年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patient is ≥ 22 years old.

  2. Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.

    In this study, peripheral vasculature is defined as outside the brain and heart.

  3. Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.

  4. Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.

  5. Target treatment area is free from prior embolization treatment.

Exclusion Criteria:

  1. Pregnant or breastfeeding.
  2. Symptoms of active infection.
  3. Patient is known to be participating in the study of an investigational drug, biologic, or device.
  4. Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
  5. Known allergy to components of Onyx™.
  6. Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
  7. More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment with Onyx LES

Device; embolization with liquid embolic

The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.

其他名称:
  • 栓塞

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Freedom from Arterial Hemorrhage
大体时间:Through 30 days post-index procedure

Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days.

Through 30 days post-index procedure
Freedom from System-related Major Adverse Events (MAE)
大体时间:Through 30 days post-index procedure

The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC.

Through 30 days post-index procedure

次要结果测量

结果测量
措施说明
大体时间
Procedural Success
大体时间:At the completion of the index procedure

successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure.

At the completion of the index procedure
Technical Success
大体时间:At the completion of the index procedure

Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment.

At the completion of the index procedure
Reintervention
大体时间:Through 30 days post-index procedure

Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure.

Through 30 days post-index procedure
Transfusions
大体时间:Through 30 days post-index procedure

Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected.

Through 30 days post-index procedure

其他结果措施

结果测量
措施说明
大体时间
Ancillary Endpoint
大体时间:Through index procedure

Duration of the index procedure

Through index procedure
Ancillary Endpoint
大体时间:Through 30 days post-index procedure

Length of hospitalization, post-index procedure

Through 30 days post-index procedure
Ancillary Endpoint
大体时间:Through 30 days post-index procedure

Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions

Through 30 days post-index procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Osman Ahmed, MD、University of Chicago

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月9日

初级完成 (估计的)

2027年4月1日

研究完成 (估计的)

2027年5月1日

研究注册日期

首次提交

2024年12月11日

首先提交符合 QC 标准的

2024年12月18日

首次发布 (实际的)

2024年12月19日

研究记录更新

最后更新发布 (实际的)

2026年10月13日

上次提交的符合 QC 标准的更新

2026年10月8日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅